These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Addressing the risk of bacterial contamination in platelets: a hospital economic perspective. Li JW; Brecher ME; Jacobson JL; Harm SK; Chen D; El-Gamil A; Dobson A; Mintz PD Transfusion; 2017 Oct; 57(10):2321-2328. PubMed ID: 28703862 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of the post-transfusion platelet increment and safety of riboflavin-based pathogen reduction technology (PRT) treated platelet products stored in platelet additive solution for 5 days or less versus 6-7 days. Kaplan A; Lindgren B; Marschner S; Aznar M; Zalba S; Sánchez P; Ayape ML; Olavarría E; Antelo ML Transfus Apher Sci; 2016 Apr; 54(2):248-52. PubMed ID: 26345109 [TBL] [Abstract][Full Text] [Related]
4. Our experience in riboflavin and ultraviolet light pathogen reduction technology for platelets: from platelet production to patient care. Jimenez-Marco T; Garcia-Recio M; Girona-Llobera E Transfusion; 2018 Aug; 58(8):1881-1889. PubMed ID: 30132911 [TBL] [Abstract][Full Text] [Related]
5. Pathogen-reduced platelets for the prevention of bleeding. Butler C; Doree C; Estcourt LJ; Trivella M; Hopewell S; Brunskill SJ; Stanworth S; Murphy MF Cochrane Database Syst Rev; 2013 Mar; (3):CD009072. PubMed ID: 23543569 [TBL] [Abstract][Full Text] [Related]
6. A comprehensive proteomics study on platelet concentrates: Platelet proteome, storage time and Mirasol pathogen reduction technology. Salunkhe V; De Cuyper IM; Papadopoulos P; van der Meer PF; Daal BB; Villa-Fajardo M; de Korte D; van den Berg TK; Gutiérrez L Platelets; 2019; 30(3):368-379. PubMed ID: 29553857 [TBL] [Abstract][Full Text] [Related]
7. Clinical and economic impacts of large volume delayed sampling and pathogen reduction technology platelet processing strategies in the United States. Earnshaw S; Beyhaghi H; McDade C; Purser M; Marriott R; Daane L; Le Coent V; Yang J; Toback S Transfusion; 2021 Oct; 61(10):2885-2897. PubMed ID: 34289101 [TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of pathogen inactivation for platelet transfusions in the Netherlands. Postma MJ; van Hulst M; De Wolf JT; Botteman M; Staginnus U Transfus Med; 2005 Oct; 15(5):379-87. PubMed ID: 16202052 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of pathogen reduction technology for plasma and platelets in Québec: A focus on potential emerging pathogens. Grégoire Y; Delage G; Custer B; Rochette S; Renaud C; Lewin A; Germain M Transfusion; 2022 Jun; 62(6):1208-1217. PubMed ID: 35560238 [TBL] [Abstract][Full Text] [Related]
10. Financial impact of alternative approaches to reduce bacterial contamination of platelet transfusions. Kacker S; Bloch EM; Ness PM; Gehrie EA; Marshall CE; Lokhandwala PM; Tobian AAR Transfusion; 2019 Apr; 59(4):1291-1299. PubMed ID: 30623459 [TBL] [Abstract][Full Text] [Related]
11. [A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy]. Vitale F; Barbieri M; Dirodi B; Vitali Rosati G; Franco E Ann Ig; 2013; 25(1):43-56. PubMed ID: 23435779 [TBL] [Abstract][Full Text] [Related]
12. Economic Implications of Pathogen Reduced and Bacterially Tested Platelet Components: A US Hospital Budget Impact Model. Prioli KM; Karp JK; Lyons NM; Chrebtow V; Herman JH; Pizzi LT Appl Health Econ Health Policy; 2018 Dec; 16(6):889-899. PubMed ID: 30062464 [TBL] [Abstract][Full Text] [Related]
13. Pathogen Reduction for Platelets-A Review of Recent Implementation Strategies. Rebulla P; Prati D Pathogens; 2022 Jan; 11(2):. PubMed ID: 35215085 [TBL] [Abstract][Full Text] [Related]
14. Peculiarities of studying the effects of pathogen reduction technologies on platelets. Osman A; Hitzler WE; Provost P Proteomics Clin Appl; 2016 Aug; 10(8):805-15. PubMed ID: 27095411 [TBL] [Abstract][Full Text] [Related]
16. Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates. Perez-Pujol S; Tonda R; Lozano M; Fuste B; Lopez-Vilchez I; Galan AM; Li J; Goodrich R; Escolar G Transfusion; 2005 Jun; 45(6):911-9. PubMed ID: 15934989 [TBL] [Abstract][Full Text] [Related]
17. Costs and benefits of bacterial culturing and pathogen reduction in the Netherlands. Janssen MP; van der Poel CL; Buskens E; Bonneux L; Bonsel GJ; van Hout BA Transfusion; 2006 Jun; 46(6):956-65. PubMed ID: 16734812 [TBL] [Abstract][Full Text] [Related]
18. A Comparison of Transfusion-Related Adverse Reactions Among Apheresis Platelets, Whole Blood-Derived Platelets, and Platelets Subjected to Pathogen Reduction Technology as Reported to the National Healthcare Safety Network Hemovigilance Module. Mowla SJ; Kracalik IT; Sapiano MRP; O'Hearn L; Andrzejewski C; Basavaraju SV Transfus Med Rev; 2021 Apr; 35(2):78-84. PubMed ID: 33934903 [TBL] [Abstract][Full Text] [Related]
19. Inactivation of human white blood cells in platelet products after pathogen reduction technology treatment in comparison to gamma irradiation. Fast LD; DiLeone G; Marschner S Transfusion; 2011 Jul; 51(7):1397-404. PubMed ID: 21155832 [TBL] [Abstract][Full Text] [Related]
20. The platelets' perspective to pathogen reduction technologies. Osman A; Hitzler WE; Provost P Platelets; 2018 Mar; 29(2):140-147. PubMed ID: 28355122 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]